Beijing Strong BiotechnologiesInc Management

Management Kriterienprüfungen 3/4

Beijing Strong BiotechnologiesInc CEO ist Xi Liu , ernannt in Mar 2011, hat eine Amtszeit von 13.67 Jahren. besitzt direkt 11.48% der Aktien des Unternehmens, im Wert von CN¥963.66M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 13.7 Jahre bzw. 5.9 Jahre.

Wichtige Informationen

Xi Liu

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	13.7yrs
Eigentum des Geschäftsführers	11.5%
Durchschnittliche Amtszeit des Managements	13.7yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.9yrs

Jüngste Management Updates

Recent updates

Is Beijing Strong BiotechnologiesInc (SZSE:300406) A Risky Investment?

Jul 25

Benign Growth For Beijing Strong Biotechnologies,Inc. (SZSE:300406) Underpins Its Share Price

Jul 03

An Intrinsic Calculation For Beijing Strong Biotechnologies,Inc. (SZSE:300406) Suggests It's 40% Undervalued

Jun 14

Is Now The Time To Put Beijing Strong BiotechnologiesInc (SZSE:300406) On Your Watchlist?

Mar 21

Improved Earnings Required Before Beijing Strong Biotechnologies,Inc. (SZSE:300406) Stock's 25% Jump Looks Justified

Mar 03

Estimating The Fair Value Of Beijing Strong Biotechnologies,Inc. (SZSE:300406)

Feb 27

Geschäftsführer

Xi Liu (62 yo)

13.7yrs

Amtszeit

CN¥2,434,400

Vergütung

Mr. Xi Liu has been General Manager and Non-Independent Director of Beijing Strong Biotechnologies, Inc. since March 2011. Mr. Liu holds Ph.D.

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Xi Liu	GM & Non-Independent Director	13.7yrs	CN¥2.43m	11.48% CN¥ 963.7m
Wei Liu	CFO & Accounting Supervisor	13.7yrs	CN¥574.90k	0.027% CN¥ 2.2m
Sheng Dan	Deputy GM & Non-Independent Director	no data	CN¥1.81m	0.061% CN¥ 5.1m
Jian Min Wang	Secretary of the Board of Directors	9.4yrs	CN¥472.80k	0.071% CN¥ 6.0m
Qinghai Yang	Deputy General Manager	no data	keine Daten	0.048% CN¥ 4.0m
Qixin Lin	Deputy General Manager	no data	keine Daten	0.054% CN¥ 4.5m

13.7yrs

Durchschnittliche Betriebszugehörigkeit

47.5yo

Durchschnittliches Alter

Erfahrenes Management: 300406Das Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (13.7 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Xi Liu	GM & Non-Independent Director	13.7yrs	CN¥2.43m	11.48% CN¥ 963.7m
Sheng Dan	Deputy GM & Non-Independent Director	4.3yrs	CN¥1.81m	0.061% CN¥ 5.1m
Zuojun Zou	Chairman of the Board	13.7yrs	CN¥2.43m	6.73% CN¥ 564.9m
Xiaolin Sun	Non-Independent Director	13.7yrs	keine Daten	8.63% CN¥ 724.6m
Aiping Luo	Non-Independent Director	13.7yrs	keine Daten	9.76% CN¥ 819.3m
Tao Jiang	Chairman of the Supervisory Committee	7.6yrs	CN¥84.00k	keine Daten
Jian Ding	Independent Director	no data	CN¥84.00k	keine Daten
Lei Fu	Independent Director	no data	CN¥84.00k	keine Daten
Yonghong Chen	Independent Director	4.3yrs	CN¥84.00k	keine Daten
Hongjun Liang	Non-Independent Director	4.3yrs	keine Daten	keine Daten
Xiaoya Wang	Non-Independent Director	1.2yrs	keine Daten	0.080% CN¥ 6.7m
Jianping Yang	Independent Director	1.2yrs	keine Daten	keine Daten

5.9yrs

Durchschnittliche Betriebszugehörigkeit

62yo

Durchschnittliches Alter

Erfahrener Vorstand: 300406Die Vorstandsmitglieder gelten als erfahren (5.9 Jahre durchschnittliche Amtszeit).

Beijing Strong BiotechnologiesInc Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Beijing Strong Biotechnologies,Inc., Annual General Meeting, Apr 22, 2024

Beijing Strong Biotechnologies,Inc. Approves Executive Appointments

Insufficient new directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.22 in 3Q 2023)

Investor sentiment deteriorates as stock falls 19%

Beijing Strong Biotechnologies,Inc. to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 18%

Second quarter 2024 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 2Q 2023)

Is Beijing Strong BiotechnologiesInc (SZSE:300406) A Risky Investment?

Benign Growth For Beijing Strong Biotechnologies,Inc. (SZSE:300406) Underpins Its Share Price

Beijing Strong Biotechnologies,Inc. to Report First Half, 2024 Results on Aug 23, 2024

An Intrinsic Calculation For Beijing Strong Biotechnologies,Inc. (SZSE:300406) Suggests It's 40% Undervalued

First quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.19 in 1Q 2023)

Upcoming dividend of CN¥0.20 per share

Beijing Strong Biotechnologies,Inc. Announces Final Cash Dividend (Tax Included) (A Shares) for 2023, Payable on 07 May 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Beijing Strong Biotechnologies,Inc., Annual General Meeting, Apr 22, 2024

Is Now The Time To Put Beijing Strong BiotechnologiesInc (SZSE:300406) On Your Watchlist?

Improved Earnings Required Before Beijing Strong Biotechnologies,Inc. (SZSE:300406) Stock's 25% Jump Looks Justified

Estimating The Fair Value Of Beijing Strong Biotechnologies,Inc. (SZSE:300406)

Investor sentiment improves as stock rises 15%

New minor risk - Share price stability

Beijing Strong Biotechnologies,Inc. to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.18 in 3Q 2022)

Beijing Strong Biotechnologies,Inc. to Report Q3, 2023 Results on Oct 25, 2023

Beijing Strong Biotechnologies,Inc. Approves Executive Appointments

Insufficient new directors

Second quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.11 in 2Q 2022)

New minor risk - Dividend sustainability

Beijing Strong Biotechnologies, Inc. (SZSE:300406) announces an Equity Buyback for CNY 80 million worth of its shares.

Beijing Strong Biotechnologies, Inc. to Report First Half, 2023 Results on Aug 10, 2023

Beijing Strong Biotechnologies, Inc. Announces Dividend on Share A for 2022, Payable on May 22, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Now 21% undervalued

Third quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 3Q 2021)

Beijing Strong Biotechnologies, Inc. (SZSE:300406) signed an Equity Transfer Agreement to acquire an additional 4.45% stake in Fuzhou Maixin Biotech. Co., Ltd. from Xinyu Yuanlang Management Consulting Partnership (Limited Partnership) for approximately CNY 130 million.

Second quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.19 in 2Q 2021)

Beijing Strong Biotechnologies, Inc. Announces Final Dividend on A Shares for the Year 2021, Payable on 27 May 2022

Beijing Strong Biotechnologies, Inc. Approves Cash Dividend for 2021

Beijing Strong Biotechnologies, Inc. Announces Final Cash Dividend Proposal for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Beijing Strong Biotechnologies, Inc. (SZSE:300406) entered into an agreement to acquire 75% stake in Wuhan Healcare Pharmaceuticals Technology Development Co., Ltd. from Xia Zhihui and Wang Ying for CNY 4 million.

Beijing Strong Biotechnologies, Inc. (SZSE:300406) announces an Equity Buyback for CNY 100 million worth of its shares.

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.15 (vs CN¥0.10 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.039 in 2Q 2020)

Beijing Strong Biotechnologies, Inc. Announces Final Cash Dividend for 2020, Payable on 27 May 2021

Full year 2020 earnings released: EPS CN¥0.21 (vs CN¥0.66 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.21 (vs CN¥0.66 in FY 2019)

New 90-day low: CN¥20.29

Beijing Strong Biotechnologies, Inc. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: CN¥23.45

Third quarter earnings released

New 90-day low - CN¥19.38

First half earnings released

New 90-day high - CN¥24.20

Beijing Strong Biotechnologies, Inc. to Report First Half, 2020 Results on Aug 28, 2020

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter